Capture more guideline-recommended actionable biomarkers and cut time to treatment by ordering liquid and tissue CGP testing at the same time.1,2*
Concurrent liquid and tissue CGP testing saves time.1,2†‡§
SWIPE TO REVEAL FULL TABLE
References: 1. Page RD, Drusbosky LM, Dada H, et al. Clinical outcomes for plasma-based comprehensive genomic profiling versus standard-of-care tissue testing in advanced non-small cell lung cancer. Clin Lung Cancer. 2022;23(1):72-81. doi:10.1016/j.cllc.2021.10.001 2. Cui W, Milner-Watts C, O’Sullivan H, et al. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. Eur J Cancer. 2022;171:44-54. doi:10.1016/j.ejca.2022.05.012 3. Guardant360® CDx Technical Information. Guardant Health, Inc. Redwood City, CA. July 2021. 4. Guardant360 TissueNext™ Assay Specifications. Guardant Health, Inc. Redwood City, CA.